Ultima-CJC no DAC 5mg

MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE GHRH Peptide ,

Products are being shipped without branding for security purposes.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of 30 amino acids. It is known for its effectiveness in boosting the secretion of growth hormone and IGF-1 while maintaining the natural pulsatility of GH release.

It is often paired with Ipamorelin to enhance specificity as a GHRH. This peptide triggers similar increases in growth hormone levels but does not stimulate appetite or elevate cortisol, acetylcholine, prolactin, or aldosterone like some other peptides. CJC-1295 is well-tolerated and complements Ipamorelin effectively.

Target Gland: Pituitary

Advantages of CJC-1295 include:

Additionally, CJC-1295 aids in promoting deep slow-wave sleep, which is crucial for muscle growth and memory retention.

There are two variants of CJC-1295:

GHRH, produced in the hypothalamus, releases growth hormone in a pulsatile manner from the pituitary. It has a very short half-life, lasting only a few minutes, which means it is quickly eliminated from the body.

The active portion of GHRH includes the first 29 amino acids, available as a manufactured peptide called Sermorelin. This was modified to extend its half-life to about 30 minutes, known as CJC-1295. Further modifications include the addition of DAC (Drug Affinity Complex), which binds to the protein albumin, extending its half-life to approximately 8 days, referred to as CJC-1295 + DAC. CJC-1295 can also be made in a non-DAC form, which creates a more natural GH spike each night.

The extended half-life allows for only one or two injections per week. However, the sustained levels can provide a constant stimulus for GH release from the pituitary via the GHRH receptor, which is not physiological. This can reduce the amplitude of GH pulses, leading to decreased stimulation of GH tissues.

Safety Considerations:

It is advisable to take 'hormone holidays' every three to six months while using long-acting CJC forms, allowing the pituitary to recuperate. During these breaks, Sermorelin can be used instead of CJC-1295 + DAC.

Taking 'hormone holidays' may also help reduce the risk of developing GH resistance, which could occur due to the formation of antibodies that bind to and deactivate GH or a reduction in GH receptors on tissues (down-regulation). While these concerns are theoretical, no long-term studies have confirmed them.

Potential side effects of CJC-1295 may include reactions at the injection site (irritation, redness, swelling, pain, itching), headaches, diarrhea, flushing (vasodilation), transient low blood pressure, nausea, and abdominal discomfort.